OBJECTIVE: To evaluate the role of diffusion-weighted MRI (DW-MRI) as an imaging biomarker for upper urinary tract cancer (UUTC) that has already metastasized or will metastasize soon. METHODS: 61 patients clinically diagnosed with UUTC were prospectively enrolled in this study. All the patients underwent MRI, including DW-MRI, prior to any interventions. Correlations between apparent diffusion coefficient (ADC) and other clinicopathological variables, including metastasis-free survival, were analysed. RESULTS: Median follow-up period was 938 days. Of the 61 patients, 12 had any metastases at the initial diagnosis. 11 patients developed metastases during the follow-up period. These 23 patients were categorized as "Metastatic". Of the remaining 38 patients, 35 with a follow-up period longer than 400 days were categorized as "Localized". ADC was significantly lower in the Metastatic category than in the Localized (p = 0.0002) category. Multivariate analysis of pre-operative variables identified ADC (cut-off value, 1.08 × 10(-3) mm(2) s(-1)) and clinical T stage based on T2 weighted MRI as an independent predictive factor of metastatic UUTC. 46 patients without any metastases during the initial diagnosis were stratified into a high-risk group (16 patients with low ADC and clinical T3-4) and a low-risk group (30 patients with high ADC or clinical Ta-2). The 3-year metastasis-free survivals were 45% and 93%, respectively. CONCLUSION: In the current study, UUTC with lower ADC value is more likely to have metastatic potential. Incorporating ADC with clinical T stage helps to differentiate metastatic UUTC at the initial diagnosis. ADVANCES IN KNOWLEDGE: DW-MRI is a potential imaging biomarker reflecting metastatic propensity of UUTC.
OBJECTIVE: To evaluate the role of diffusion-weighted MRI (DW-MRI) as an imaging biomarker for upper urinary tract cancer (UUTC) that has already metastasized or will metastasize soon. METHODS: 61 patients clinically diagnosed with UUTC were prospectively enrolled in this study. All the patients underwent MRI, including DW-MRI, prior to any interventions. Correlations between apparent diffusion coefficient (ADC) and other clinicopathological variables, including metastasis-free survival, were analysed. RESULTS: Median follow-up period was 938 days. Of the 61 patients, 12 had any metastases at the initial diagnosis. 11 patients developed metastases during the follow-up period. These 23 patients were categorized as "Metastatic". Of the remaining 38 patients, 35 with a follow-up period longer than 400 days were categorized as "Localized". ADC was significantly lower in the Metastatic category than in the Localized (p = 0.0002) category. Multivariate analysis of pre-operative variables identified ADC (cut-off value, 1.08 × 10(-3) mm(2) s(-1)) and clinical T stage based on T2 weighted MRI as an independent predictive factor of metastatic UUTC. 46 patients without any metastases during the initial diagnosis were stratified into a high-risk group (16 patients with low ADC and clinical T3-4) and a low-risk group (30 patients with high ADC or clinical Ta-2). The 3-year metastasis-free survivals were 45% and 93%, respectively. CONCLUSION: In the current study, UUTC with lower ADC value is more likely to have metastatic potential. Incorporating ADC with clinical T stage helps to differentiate metastatic UUTC at the initial diagnosis. ADVANCES IN KNOWLEDGE: DW-MRI is a potential imaging biomarker reflecting metastatic propensity of UUTC.
Authors: Robert Abouassaly; Shabbir M H Alibhai; Nasir Shah; Narhari Timilshina; Neil Fleshner; Antonio Finelli Journal: Urology Date: 2010-06-19 Impact factor: 2.649
Authors: Vitaly Margulis; Ramy F Youssef; Pierre I Karakiewicz; Yair Lotan; Christopher G Wood; Richard Zigeuner; Eiji Kikuchi; Alon Weizer; Jay D Raman; Mesut Remzi; Marco Roscigno; Francesco Montorsi; Christian Bolenz; Wassim Kassouf; Shahrokh F Shariat Journal: J Urol Date: 2010-06-17 Impact factor: 7.450
Authors: Anwar R Padhani; Guoying Liu; Dow Mu Koh; Thomas L Chenevert; Harriet C Thoeny; Taro Takahara; Andrew Dzik-Jurasz; Brian D Ross; Marc Van Cauteren; David Collins; Dima A Hammoud; Gordon J S Rustin; Bachir Taouli; Peter L Choyke Journal: Neoplasia Date: 2009-02 Impact factor: 5.715
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Irene Marco-Rius; Jeremy W Gordon; Aras N Mattis; Robert Bok; Romelyn Delos Santos; Subramanian Sukumar; Peder E Z Larson; Daniel B Vigneron; Michael A Ohliger Journal: J Magn Reson Imaging Date: 2017-04-17 Impact factor: 4.813
Authors: Hwang Sung Tae; Sung Deuk Jae; Yang Kyung Sook; Sim Ki Choon; Han Na Yeon; Park Beom Jin; Kim Min Ju; Cho Sung Bum Journal: Br J Radiol Date: 2017-08-22 Impact factor: 3.039